Top Story

A look at coagulation assays for target-specific oral anticoagulants

May 6, 2015

Target-specific oral anticoagulants have emerged as alternative therapeutic options for the management of thrombembolic disorders.

Before the development of target-specific oral anticoagulants (TSOACs), the oral vitamin K antagonist warfarin was the mainstay of treatment and prophylaxis for thromboembolism. Although effective, the use of oral vitamin K antagonists requires routine laboratory monitoring, owing to their narrow therapeutic index, slow onset of action, and potential for multiple drug-drug and food interactions. Frequent laboratory monitoring and dose adjustment result in poor patient compliance and difficulty maintaining patients within a therapeutic window. These limitations led to the development of TSOACs (see Table 1).

Meeting News Coverage

Younger age linked to poorer outcomes after pulmonary valve replacement

May 6, 2015
Young patients with congenital heart disease who underwent pulmonary valve replacement had a higher risk for reintervention than adults, according to data from a…
Barry J. Maron, MD In the Journals

Mortality rates decrease for adult hypertrophic cardiomyopathy

May 6, 2015
Study findings of long-term outcomes in adults with hypertrophic cardiomyopathy found that disease-related mortality rates have dropped to approximately 0.5% per year…
Salim S. Virani, MD PhD, FACC, FAHA Meeting News Coverage

Outpatient CVD care delivery similar between physician, nonphysician primary care providers

May 5, 2015
The quality of care for patients with CVD provided by primary care physicians, nurse practitioners and physician assistants in the outpatient setting is comparable…
In the Journals

Insulin resistance increases CVD risk in postmenopausal women without diabetes

May 5, 2015
Postmenopausal women with measures of insulin resistance or impaired fasting glucose have an increased risk for cardiovascular disease even if they do not have diabetes…
More News Headlines »
CME
Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

Severe Hypertriglyceridemia: Confronting the Complex Issues in Etiology and Treatment

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent, yet modifiable, risk factor for atherosclerotic disease, pancreatitis, and…
More »
Meeting News Coverage Video
VIDEO: Nathaniel Reichek, MD, shares insights on impact of PROMISE trial data

VIDEO: Nathaniel Reichek, MD, shares insights on impact of PROMISE trial data

May 3, 2015
SAN DIEGO — Nathaniel Reichek, MD, director of cardiac imaging services at St. Francis Hospital, Roslin, NY and…
More »
CME
Best of Lipid Forum III

Best of Lipid Forum III

This activity is supported by an educational grant from Amgen, Inc.

Appropriate therapies for various dyslipidemias remain a challenge for practitioners struggling to reduce residual risk…
More »
morganatic-roan